HERZLIYA, Israel and Calgary, AB, Oct. 16, 2024 /CNW/ — Innocan Pharma Corporation INNO IP INNPF (“Innocan” or the “Company”), a pioneer in chronic pain management via Liposomal CBD drug products, is pleased to announce that it will be presenting at the 2024 ThinkEquity Investor Conference taking place on October 30 at the Mandarin Oriental Hotel in New York, NY.
The Company will be discussing its recently achieved significant regulatory milestones, in particular, securing a U.S. Food and Drug Administration (FDA) approval for a 505(2)(b) abbreviated pathway for its human health applications. This included a sponsor fee waiver and an Investigational New Animal Drug number (INAD) for its animal health applications from the FDA Center for Veterinary Medicine.
Iris Bincovich, CEO of Innocan Pharma, will be presenting at the investor conference on Wednesday, October 30th at 2:00pm ET (also viewable online at the conference portal). The Company’s executive team will be available for one-on-one meetings at the event.
Interested investors can register to meet with Innocan leadership at:
https://www.meetmax.com/sched/event_106721/conference_register.html
The conference will feature over 75 companies in diverse technology, biotechnology and energy fields, presenting in half-hour increments, and will offer one-on-one meetings with investors and analysts. With over 600 leading industry executives, institutional investors, and family offices in attendance, the ThinkEquity conference offers an excellent platform to showcase Innocan and build meaningful connections with top investors and leading industry executives.
As part of our ongoing commitment to enhancing communication, Innocan is proud to announce the relaunch of its newly updated website. The redesign offers a streamlined, intuitive interface, making it easier for collaborators, pharmaceutical companies, and investors to access key information and stay updated on the Company’s progress.
About Innocan Pharma:
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.
For more information: www.innocanpharma.com
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Logo: https://www.wallstreetpr.com/wp-content/uploads/2024/10/innocan_pharma_corporation_logo-1.jpg
View original content:SOURCE Innocan Pharma Corporation
View original content: http://www.newswire.ca/en/releases/archive/October2024/16/c5652.html
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
